Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

Université de Montréal

$17,500.00

Characterization of tumor-infiltrating T lymphocytes expressing PD-1 as a source of anti-tumoral cells for adoptive cell transfer immunotherapy

EF 2019-20

Résumé
"Cancer immunotherapy currently shows great promise in the treatment of a growing number of cancers, including melanoma, exploiting the patient's own immune system to fight cancer. A novel immunotherapeutic method involves the transfer of adoptive T cells (ACT) which naturally infiltrate tumors. These cells are expanded ex vivo and reinfused in large number to the patient. This method yields clinical responses in up to 50% of metastatic melanoma patients but is hindered by the low number of tumor-reactive cells in the infused product. We thus propose to elaborate a method to enhance the number of tumor-reactive T cells in the end product. PD-1, a marker of T cell activation, will serve as a marker of T cells having recognized the tumor's neoantigens. Therefore, using a clinical grade sorter, we will demonstrate that selecting PD-1+ TIL enriches the transfusion product in tumor-reactive T cells, and has the potential to enhance ACT. To achieve this, we will characterize and compare the immune features of PD-1+ sorted TIL to the PD-1- sorted TIL and standard bulk expanded TIL, by multi-parametric flow cytometry. We will assess proliferative properties by cell count and CFSE dilutions and T cell clonality by TCR sequencing for each TIL population. Tumors from 6 melanoma patients were excised, sequenced for mutation identification and peptide synthesis and used to generate cell lines, allowing us to assess tumor-specific recognition by performing cocultures of TIL and tumor cell lines or peptide-pulsed B cells, quantified by OX40 and 4-1BB de novo upregulation and IFNγ secretion. We wish to show that the PD-1+ TIL enrichment would represent a suitable approach in the improvement of ACT immunotherapy and will support a clinical trial application to Health Canada."
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
428676
Name
April William
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterization of tumor-infiltrating T lymphocytes expressing PD-1 as a source of anti-tumoral cells for adoptive cell transfer immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adoptive T Cell Transfer; Cancer Immunotherapy; Cellular Therapy; Clinical-Grade Cell Sorting; Melanoma; Neoantigens; Programmed Cell Death Protein 1; Tumor-Infiltrating Lymphocytes
Abstract
"Cancer immunotherapy currently shows great promise in the treatment of a growing number of cancers, including melanoma, exploiting the patient's own immune system to fight cancer. A novel immunotherapeutic method involves the transfer of adoptive T cells (ACT) which naturally infiltrate tumors. These cells are expanded ex vivo and reinfused in large number to the patient. This method yields clinical responses in up to 50% of metastatic melanoma patients but is hindered by the low number of tumor-reactive cells in the infused product. We thus propose to elaborate a method to enhance the number of tumor-reactive T cells in the end product. PD-1, a marker of T cell activation, will serve as a marker of T cells having recognized the tumor's neoantigens. Therefore, using a clinical grade sorter, we will demonstrate that selecting PD-1+ TIL enriches the transfusion product in tumor-reactive T cells, and has the potential to enhance ACT. To achieve this, we will characterize and compare the immune features of PD-1+ sorted TIL to the PD-1- sorted TIL and standard bulk expanded TIL, by multi-parametric flow cytometry. We will assess proliferative properties by cell count and CFSE dilutions and T cell clonality by TCR sequencing for each TIL population. Tumors from 6 melanoma patients were excised, sequenced for mutation identification and peptide synthesis and used to generate cell lines, allowing us to assess tumor-specific recognition by performing cocultures of TIL and tumor cell lines or peptide-pulsed B cells, quantified by OX40 and 4-1BB de novo upregulation and IFNγ secretion. We wish to show that the PD-1+ TIL enrichment would represent a suitable approach in the improvement of ACT immunotherapy and will support a clinical trial application to Health Canada."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
April, William
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~